Please wait while the formulary information is being retrieved.
AMJEVITA (adalimumab-atto)
- Crohn's disease
- polyarticular juvenile idiopathic arthritis
20 mg/0.4 mL subcutaneous syringe
- Dosage information is not available
40 mg/0.8 mL subcutaneous syringe
- Inject 0.8 milliliter (40 mg) by subcutaneous route every 2 weeks in the abdomen or thigh (rotate sites)
Default screening record
- Inject 0.8 milliliter (40 mg) by subcutaneous route every 2 weeks in the abdomen or thigh (rotate sites)
- Inject 0.8 milliliter (40 mg) by subcutaneous route once weekly in the abdomen or thigh (rotate sites)
- Inject 1.6 milliliters (80 mg) by subcutaneous route once daily in the abdomen or thigh (rotate sites) for 2 consecutive days
- Inject 1.6 milliliters (80 mg) by subcutaneous route in the abdomen or thigh (rotate sites) on days1 and 2; inject 1.6 ml(80 mg) day 15; day 29 start 0.8 ml(40 mg) every 2 weeks
- Inject 1.6 milliliters (80 mg) by subcutaneous route in the abdomen or thigh (rotate sites) on days 1And 2; inject 1.6 ml(80 mg) day 15; day 29 start 0.8 ml(40 mg) every week
- Inject 1.6 milliliters (80 mg) by subcutaneous route in the abdomen or thigh (rotate sites) on day 1; after one week start 0.8 ml (40 mg) every 2 weeks
- Inject 1.6 milliliters (80 mg) by subcutaneous route every 2 weeks inthe abdomen or thigh (rotate sites)
- Inject 1.6 milliliters (80 mg) by subcutaneous route once in the abdomen or thigh
- Inject 3.2 milliliters (160 mg) by subcutaneous route once in the abdomen or thigh
- Inject 3.2 milliliters (160 mg) by subcutaneous route in the abdomen or thigh (rotate sites) day 1; inject 1.6 ml (80 mg) day 15; day 29 start 0.8 ml(40 mg) every 2 weeks
- Inject 3.2 milliliters (160 mg) by subcutaneous route in the abdomen or thigh (rotate sites) day 1; inject 1.6 ml (80 mg) day 15; day 29 start 0.8 ml(40 mg) every week
- abatacept (with maltose)
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Orencia (with Maltose)
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- tofacitinib
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- Xeljanz
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- Actemra
- anakinra
- Arcalyst
- Azasan
- azathioprine
- azathioprine sodium
- canakinumab (PF)
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Ilaris (pf)
- Imuran
- Kineret
- mercaptopurine
- Purinethol
- rilonacept
- tocilizumab
- Versacloz
Severe
Moderate
- None
- Active tuberculosis
- Extrapulmonary pneumocystosis
- Pneumocystis jirovecii pneumonia
- Sepsis
Contraindicated
- Basal cell carcinoma of skin
- Chronic heart failure
- Chronic infection
- Demyelinating disorder
- Guillain-barre syndrome
- Hepatosplenic t-cell lymphoma
- Inactive tuberculosis
- Leukemia
- Malignancy
- Malignant lymphoma
- Neutropenic disorder
- Opportunistic fungal infection
- Opportunistic viral infection
- Pancytopenia
- Severe infection
- Squamous cell carcinoma
- Thrombocytopenic disorder
- Viral hepatitis B
Severe
Moderate
- Multiple sclerosis
AMJEVITA (adalimumab-atto)
- Crohn's disease
- polyarticular juvenile idiopathic arthritis
- Dehydration
- Infection
- Lupus-like syndrome
- Skin rash
- Upper respiratory infection
- Headache disorder
- Injection site sequelae
- Nausea
- Pharyngitis
- Pruritus of skin
- Sinusitis
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Accidental injury
- Acute myocardial infarction
- Agranulocytosis
- Asthma
- Atrial fibrillation
- Avascular necrosis of bone
- Biliary calculus
- Bronchospastic pulmonary disease
- Cardiac arrest
- Cardiac arrhythmia
- Cataracts
- Chest pain
- Chronic heart failure
- Cystitis
- Dyspnea
- Erysipelas
- Erythrocytosis
- Flu-like symptoms
- Fracture
- Fungal infection
- Gastrointestinal hemorrhage
- Hepatic necrosis
- Herpes zoster
- Hypertension
- Hypertensive crisis
- Increased alanine transaminase
- Ketosis
- Kidney stone
- Leg vein thrombosis
- Leukopenia
- Malignant lymphoma
- Monoclonal gammopathy
- Multiple sclerosis
- Palpitations
- Pericardial effusion
- Pericarditis
- Peripheral edema
- Pneumonia
- Pseudohypoparathyroidism
- Pyelonephritis
- Reactivated tuberculosis
- Secondary polycythemia
- Subdural intracranial hemorrhage
- Syncope
- Tachycardia
- Urinary tract infection
- Acute abdominal pain
- Acute confusion
- Arthritis
- Back pain
- Cramps
- Esophagitis
- Gastroenteritis
- Hematuria
- Hypercholesterolemia
- Hyperlipidemia
- Impaired wound healing
- Injection site erythema
- Muscle weakness
- Pain in extremities
- Paresthesia
- Pelvic pain
- Pleural effusions
- Septic arthritis
- Synovitis
- Tremor
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Active tuberculosis
- Anaphylaxis
- Angioedema
- Aplastic anemia
- Appendicitis
- Autoimmune hepatitis
- Bacterial sepsis
- Basal cell carcinoma of skin
- Blastomycosis
- Cellulitis
- Cerebrovascular accident
- Cholecystitis
- Coccidioidomycosis
- Cutaneous vasculitis
- Deep venous thrombosis
- Demyelinating disorder
- Diverticulitis of gastrointestinal tract
- Drug-exacerbated psoriasis
- Erythema multiforme
- Guillain-barre syndrome
- Heart failure
- Hepatic failure
- Hepatitis
- Hepatosplenic t-cell lymphoma
- Histoplasmosis
- Hypersensitivity drug reaction
- Intestinal perforation
- Legionnaires' disease
- Leukemia
- Listeriosis
- Malignancy
- Malignant melanoma
- Merkel cell carcinoma
- Opportunistic fungal infection
- Optic neuritis
- Pancreatitis
- Pancytopenia
- Protozoal infection
- Pulmonary fibrosis
- Pulmonary thromboembolism
- Reactivation of hepatitis B
- Sarcoidosis
- Squamous cell carcinoma
- Stevens-johnson syndrome
- Thrombocytopenic disorder
- Thrombotic disorder
- Vasculitis
- Worsening of chronic heart failure
Less Severe
- Alopecia
- Fever
- Granuloma annulare
- Lichenoid dermatitis drug eruption
- Menstrual disorder
- Urticaria
Contraindicated
None
Severe Precaution
Adalimumab
No safety and efficacy established age <2 years. Possible malignancy, lymphoma, hepatosplenic T-cell lymphoma risk. Risk of neutropenia, streptococcal pharyngitis, appendicitis, herpes zoster and simplex, myositis, and metrorrhagia.
- 1 Day – 2 Years
- No safety and efficacy established age <2 years. Possible malignancy, lymphoma, hepatosplenic T-cell lymphoma risk. Risk of neutropenia, streptococcal pharyngitis, appendicitis, herpes zoster and simplex, myositis, and metrorrhagia.
Management or Monitoring Precaution
Adalimumab
Higher incidence of infection in pediatrics. Monitor for lymphoma, malignancy, leukemia, appendicitis and rare report of hepatosplenic T-cell lymphoma.
- 2 Years – 18 Years
- Higher incidence of infection in pediatrics. Monitor for lymphoma, malignancy, leukemia, appendicitis and rare report of hepatosplenic T-cell lymphoma.
Adalimumab
- Severity Level:
2
- Additional Notes: Crosses placenta;human and animal data have shown no known embryo/fetal toxicity
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Adalimumab
Limited data suggest low levels excreted; infant absorption unlikely
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Limited data suggest low levels excreted; infant absorption unlikely |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This medication can decrease your body's ability to fight an infection. This effect can lead to very serious (possibly fatal) infections (such as fungal infections, bacterial infections including tuberculosis). Tell your doctor your medical history, especially of past/recent/current infections.<br /><br />You should also tell your doctor if you have lived or traveled in areas where certain fungal infections (such as coccidioidomycosis, histoplasmosis) are common or if you have been near someone with tuberculosis. Areas where these types of fungal infections are commonly found include the Ohio and Mississippi River valleys and the southwestern United States. Tell your doctor right away if you develop signs of infection (see Side Effects section).<br /><br /> Your doctor will test you for tuberculosis (TB) infection before and during treatment with this drug. If you are diagnosed with TB, your doctor will first prescribe treatment for this to prevent a serious TB infection while using adalimumab. Though it is very unlikely to happen, there is a risk (especially in children/teens/young adults) of developing cancer (such as lymphoma, skin cancer) due to this medication or due to your medical condition.<br /><br />Discuss the risks and benefits of treatment with your doctor. Tell your doctor right away if you develop symptoms such as a fever that doesn't go away, unusual lumps/growths, swollen glands, unexplained weight loss, or night sweats.
Formulary Reference Tool